Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Arlington Heights, IL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Danville, PA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Danville, PA
Click here to add this to my saved trials
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Birmingham, AL
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Gainesville, FL
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Sarasota, FL
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Durham, NC
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fayetteville, AR
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Baltimore, MD
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lake Success, NY
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Southington, CT
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Southington, CT
Click here to add this to my saved trials
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Dallas, TX
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Atlanta, GA
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Highland, CA
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Highland, CA
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Morristown, NJ
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Somerville, NJ
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Somerville, NJ
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Germantown, TN
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Houston, TX
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Burlington, VT
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Chandler, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Gilbert, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Mesa, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Pasadena, CA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Santa Barbara, CA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Aurora, CO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Colorado Springs, CO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Denver, CO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Altamonte Springs, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Altamonte Springs, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Miami, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Ocala, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Orlando, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Tampa, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Niles, IL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Niles, IL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lafayette, IN
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lafayette, IN
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Ames, IA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Ames, IA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
New Orleans, LA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Baltimore, MD
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Jefferson City, MO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lincoln, NE
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials